This article is not legal advice, and it does not offer a legal opinion on whether any specific monitoring system complies with Canadian law for any specific resident or facility. It covers Ontario law only — Ontario’s Personal Health Information Protection Act (PHIPA), Health Care Consent Act (HCCA), and Substitute Decisions Act (SDA). Provincial law on health privacy and capacity varies significantly across Canada, and no other province’s framework is addressed here. Anyone considering deploying monitoring technology, particularly for residents whose capacity to consent may be reduced, should get independent legal advice specific to their jurisdiction, facility, and technology.

What’s actually settled

Two general legal frameworks are genuinely well established in Ontario, and it’s worth being precise about what they actually require.

Consent for personal health information. Under PHIPA, health information custodians — including long-term care homes, and explicitly extending to “agents and service providers acting on their behalf, including medical technology companies” — must obtain consent to collect, use, or disclose personal health information, with narrow exceptions like emergencies. Residents retain the right to refuse or withdraw that consent. A 2020 amendment added a requirement for electronic audit logs tracking every access to an electronic health record — part of a broader regulatory push toward more granular accountability.

Capacity and substitute decision-making. Ontario law presumes a person is capable of making their own decisions unless a formal capacity assessment finds otherwise, across six specific domains: health care, nutrition, shelter, clothing, hygiene, and safety — the domain most directly relevant to monitoring technology, since fall detection and wandering alerts are typically marketed on safety grounds. Where someone is found incapable in a given domain, a substitute decision-maker consents on their behalf, and Ontario’s Health Care Consent Act governs consent processes for long-term care admission and personal assistance services specifically.

Federally, PIPEDA and the Privacy Commissioner’s video surveillance guidance set general private-sector conditions: overt surveillance should have a documented business reason, a written policy, minimized camera scope, disclosure to those being monitored, secure storage, and timely destruction of recordings. Covert surveillance is treated as “extremely privacy-invasive” and reserved for the most limited cases. This guidance matters as background, but it’s worth flagging directly: it was written for general commercial use, not for long-term care or for residents with cognitive impairment specifically.

What’s genuinely unsettled — and this matters

Here’s where honesty requires saying plainly: nobody has clearly mapped these general rules onto sensor, camera, or AI monitoring technology specifically.

No Ontario regulator has issued guidance addressing remote monitoring, wearables, cameras, or voice/AI devices in long-term care by name. PHIPA’s general consent principles apply in the sense that PHIPA covers personal health information however it’s collected — but exactly how a regulator would treat, say, a continuous ambient sensor or an always-listening voice device hasn’t been directly addressed anywhere this research found.

Similarly, no case law or regulatory guidance applies the HCCA/SDA capacity framework specifically to monitoring technology. Reading “safety” as the relevant capacity domain for a bed-exit sensor or fall-detection wearable is a reasonable inference from how the law is structured — but it’s an inference, not a documented ruling. Treat it as a starting point for a conversation with legal counsel, not as settled law.

There’s also an unresolved question about how PHIPA and PIPEDA interact when a technology vendor is supplying a device to an Ontario long-term care home — the vendor may be acting as the home’s PHIPA “agent” for health information while also being separately subject to PIPEDA as a commercial entity. No source located in this research definitively maps how these two regimes interact for a specific device or vendor relationship.

Why this is genuinely hard, not just a compliance checklist

A 2025 ethics paper in Sensors — a European source, not a Canadian one, but the most directly relevant analysis found on this specific question — frames the underlying difficulty as two real tensions, not a box-ticking exercise:

Autonomy versus safety. A sensor itself doesn’t override anyone’s choices. What determines whether a resident’s autonomy is supported or undermined is the caregiver’s response to what the sensor flags. A device that notices a resident leaving their unit unaccompanied can prompt either a supportive check-in or a restrictive intervention — the technology doesn’t decide which.

Privacy versus protection. Sensing methods that don’t produce an image — radar or motion sensors, for instance — may preserve dignity better than cameras specifically, while potentially offering comparable safety benefit, because there’s no visual record being captured or stored.

The same paper proposes seven practical principles: deploy technology only where the probability of real benefit is high; minimize data collection and purge it automatically; secure it with restricted access and encryption; use transparent system design; inform residents and families without stigmatizing signage; involve relatives and honor documented preferences when someone can’t consent themselves; and engage stakeholders broadly, acknowledging that attitudes toward monitoring vary by culture and individual.

One caveat has to travel with all of this, and it’s important: the same researchers state directly that “scientific evidence of the benefits remains sparse” for sensor technology in dementia populations specifically — most existing research shows a device works technically, not that it actually improves outcomes for the people using it. There’s currently no consensus that any specific type of this technology qualifies as a clinical standard. The ethical framework above is a useful way to think through a decision; it isn’t proof the underlying technology delivers what it claims.

The design-inclusion angle Canadian researchers are raising

Two Canadian sources, both connected to the AGE-WELL network, add a different but related point. Older adults themselves, reflecting through AGE-WELL’s Older Adults and Caregivers Advisory Committee and a Vancouver-based seniors’ research group, flag “digital ageism” — assumptions baked into how age-tech gets designed and marketed — and argue for older adults leading design decisions, not just being consulted after a product already exists. A companion AGE-WELL symposium piece recommends building ethical consideration into technology “from start to finish” rather than retrofitting it later.

Neither source addresses privacy law directly. Their point is broader: a technology can satisfy every formal consent requirement and still treat older adults as passive subjects of monitoring rather than participants in decisions about it. That’s a design critique sitting alongside the legal question, not a restatement of it.

What operators can actually do with this

Legal compliance and good ethical practice aren’t the same checklist, and satisfying one doesn’t guarantee the other. A structuring approach — borrowed from the research above, not a Canadian regulatory standard — separates the two:

The compliance layer: obtain and document consent under PHIPA; determine whether HCCA/SDA capacity processes apply for a given resident and the safety domain specifically; apply PIPEDA/OPC’s general surveillance conditions (documented purpose, minimized scope, disclosure, security, retention limits) even though that guidance wasn’t written for long-term care.

The practice layer, on top of compliance, not instead of it: Is there documented evidence of benefit for this specific use, not just the technology category generally? Is data collection minimized and time-limited? Is the least privacy-invasive option being used that still meets the safety goal? Are residents and families genuinely informed, without alarmist or stigmatizing framing? Is the resident’s own previously expressed wishes documented and followed, especially when a substitute decision-maker is involved? Is the arrangement revisited over time rather than treated as a one-time decision?

What this article doesn’t settle

  • This is not legal advice, and it should not be treated as a substitute for advice from a lawyer licensed in the relevant jurisdiction.
  • Only Ontario law is covered. Other provinces have their own frameworks not addressed here.
  • No regulator or court has directly addressed monitoring technology specifically under PHIPA, PIPEDA, or the HCCA/SDA. Everything connecting the general law to a specific device is inference, clearly labeled as such throughout this piece.
  • How PHIPA and PIPEDA interact for a specific vendor relationship is an open question, not something this article resolves.
  • The ethical framework here is European, not Canadian — a useful way to think, not Canadian regulatory guidance.
  • Evidence that monitoring technology actually delivers claimed safety benefits is thin, according to the researchers who study it most directly.

What this means in practice

For operators: general consent and capacity obligations genuinely apply, but the specific application to any given monitoring technology hasn’t been authoritatively settled by anyone this research found — treat that as a starting point for a conversation with legal counsel, not a finished answer. Being the organization that asks these questions honestly, including the uncomfortable ones about evidence and dignity, is itself a credibility signal worth taking seriously.

For families: if a home is introducing new monitoring technology for a parent, reasonable questions include what specific benefit it’s meant to provide, who consented and how, what happens to the data, and whether it was chosen partly because it’s less invasive than the alternatives — not just whether it’s the most advanced option available.

Neither reading is medical or legal advice. See our medical disclaimer for what that means.